China · Delayed Price · Currency is CNY Luyan Pharma Statistics
Total Valuation
Luyan Pharma has a market cap or net worth of CNY 4.18 billion. The enterprise value is 8.82 billion.
| Market Cap | 4.18B |
| Enterprise Value | 8.82B |
Important Dates
The next confirmed earnings date is Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | Jul 10, 2026 |
Share Statistics
Luyan Pharma has 388.52 million shares outstanding. The number of shares has increased by 0.76% in one year.
| Current Share Class | 388.52M |
| Shares Outstanding | 388.52M |
| Shares Change (YoY) | +0.76% |
| Shares Change (QoQ) | -6.57% |
| Owned by Insiders (%) | 3.50% |
| Owned by Institutions (%) | 0.64% |
| Float | 232.41M |
Valuation Ratios
The trailing PE ratio is 15.59.
| PE Ratio | 15.59 |
| Forward PE | n/a |
| PS Ratio | 0.20 |
| PB Ratio | 1.26 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | 24.21 |
| P/OCF Ratio | 11.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.80, with an EV/FCF ratio of 51.10.
| EV / Earnings | 32.76 |
| EV / Sales | 0.41 |
| EV / EBITDA | 12.80 |
| EV / EBIT | 16.04 |
| EV / FCF | 51.10 |
Financial Position
The company has a current ratio of 1.10, with a Debt / Equity ratio of 1.59.
| Current Ratio | 1.10 |
| Quick Ratio | 0.75 |
| Debt / Equity | 1.59 |
| Debt / EBITDA | 7.66 |
| Debt / FCF | 30.57 |
| Interest Coverage | 3.35 |
Financial Efficiency
Return on equity (ROE) is 8.12% and return on invested capital (ROIC) is 5.03%.
| Return on Equity (ROE) | 8.12% |
| Return on Assets (ROA) | 2.66% |
| Return on Invested Capital (ROIC) | 5.03% |
| Return on Capital Employed (ROCE) | 14.11% |
| Weighted Average Cost of Capital (WACC) | 3.13% |
| Revenue Per Employee | 3.75M |
| Profits Per Employee | 47,075 |
| Employee Count | 5,722 |
| Asset Turnover | 1.66 |
| Inventory Turnover | 7.25 |
Taxes
In the past 12 months, Luyan Pharma has paid 96.52 million in taxes.
| Income Tax | 96.52M |
| Effective Tax Rate | 26.67% |
Stock Price Statistics
The stock price has increased by +32.51% in the last 52 weeks. The beta is -0.01, so Luyan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | +32.51% |
| 50-Day Moving Average | 10.89 |
| 200-Day Moving Average | 13.70 |
| Relative Strength Index (RSI) | 47.41 |
| Average Volume (20 Days) | 13,400,538 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Luyan Pharma had revenue of CNY 21.43 billion and earned 269.36 million in profits. Earnings per share was 0.69.
| Revenue | 21.43B |
| Gross Profit | 1.48B |
| Operating Income | 550.20M |
| Pretax Income | 361.88M |
| Net Income | 269.36M |
| EBITDA | 629.01M |
| EBIT | 550.20M |
| Earnings Per Share (EPS) | 0.69 |
Balance Sheet
The company has 648.67 million in cash and 5.28 billion in debt, with a net cash position of -4.63 billion or -11.92 per share.
| Cash & Cash Equivalents | 648.67M |
| Total Debt | 5.28B |
| Net Cash | -4.63B |
| Net Cash Per Share | -11.92 |
| Equity (Book Value) | 3.33B |
| Book Value Per Share | 8.53 |
| Working Capital | 967.85M |
Cash Flow
In the last 12 months, operating cash flow was 376.57 million and capital expenditures -203.89 million, giving a free cash flow of 172.69 million.
| Operating Cash Flow | 376.57M |
| Capital Expenditures | -203.89M |
| Depreciation & Amortization | 78.81M |
| Net Borrowing | 263.86M |
| Free Cash Flow | 172.69M |
| FCF Per Share | 0.44 |
Margins
Gross margin is 6.92%, with operating and profit margins of 2.57% and 1.26%.
| Gross Margin | 6.92% |
| Operating Margin | 2.57% |
| Pretax Margin | 1.69% |
| Profit Margin | 1.26% |
| EBITDA Margin | 2.94% |
| EBIT Margin | 2.57% |
| FCF Margin | 0.81% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 3.25%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 3.25% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 112.83% |
| FCF Payout Ratio | 78.75% |
| Buyback Yield | -0.76% |
| Shareholder Yield | 2.49% |
| Earnings Yield | 6.44% |
| FCF Yield | 4.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 29, 2019. It was a forward split with a ratio of 1.7.
| Last Split Date | May 29, 2019 |
| Split Type | Forward |
| Split Ratio | 1.7 |
Scores
Luyan Pharma has an Altman Z-Score of 2.39 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.39 |
| Piotroski F-Score | 5 |